===
EQS-News: Eckert & Ziegler SE / Key word(s): Conference/Miscellaneous
Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA
2024-05-31 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
BOSTON, Mass., May 31, 2024 - Eckert & Ziegler reports about the successful completion of the 2nd annual Boston
Radionuclide Theranostics Forum, reaffirming its pivotal role in the field of radiopharmaceuticals. Building on the
momentum of last year's inaugural event, the Forum once again brought together leading experts, potential and existing
partners, and key industry players to delve into the pressing topics and innovations driving the rapidly evolving
radiotheranostics market.
The Forum, held on May 30, 2024, explored solutions to challenges in healthcare system readiness, isotope production as
well as development of radiopharmaceuticals and successful deals in the radiotherapeutic space. This year's event saw
an even larger turnout, reflecting the growing interest and importance of this annual gathering.
"Numerous announcements prove that the radiopharmaceutical market is more dynamic and vibrant than ever before. We were
honored to host the second Radionuclide Theranostics Forum in Boston in such exciting times," said Dr. Harald
Hasselmann, CEO of Eckert & Ziegler SE. "This year's discussions focused on these new developments, while building on
the foundations of 2023. Always having in mind future market challenges, the ideas, and partnerships that emerged here
will advance precision oncology worldwide in the long term."
Initiated and sponsored by Eckert & Ziegler, the Boston Radionuclide Theranostics Forum has quickly become a fixture in
the nuclear medicine calendar. The half-day event featured talks by over a dozen international experts and executives
from clinical, industry, and research backgrounds. Attendees engaged in dynamic panel discussions, further solidifying
the Forum's reputation as a critical platform for knowledge exchange and innovation in radiotheranostics.
Attendance was by invitation only, and the event once again reached full capacity. The 3^rd edition of the Forum will
be held on May 29, 2025. As it continues to grow and evolve, Eckert & Ziegler is committed to fostering a collaborative
environment that advances the science and application of radiotheranostics, ultimately improving patient outcomes
worldwide.
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1,000 employees is a leading specialist for isotope-related components in nuclear
medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical
industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN
DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing
karolin.riehle@ezag.de / jan.schoepflin@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

2024-05-31 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Eckert & Ziegler SE 

Robert-Rössle-Str.10
13125 Berlin
Germany

Phone:        +49 30 941084-138 
Fax:          +49 30 941084-0 
Internet:     www.ezag.de 
ISIN:         DE0005659700 
WKN:          565970 
Indices:      SDAX, TecDax, 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1914763

End of News EQS News Service
===
1914763 2024-05-31 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1914763&application_name=news

END) Dow Jones Newswires

May 31, 2024 03:00 ET (07:00 GMT)